Deruxtecan / 5 mg
Safety Information
Hazard Statements
Pictograms
Properties
| Signal Word | Warning |
Product Description
Deruxtecan is a targeted cancer therapy designed to enhance the effectiveness of existing treatments. It works by inhibiting a protein that helps tumors grow and spread, potentially slowing tumor growth and improving patient outcomes. This medication is administered through intravenous infusion and is part of a growing class of drugs known as antibody-drug conjugates. Deruxtecan has shown promise in clinical trials for various types of cancers, including breast, lung, and ovarian cancers. Its mechanism of action involves binding to a specific target on cancer cells, leading to cell death without harming healthy cells. This precision approach aims to minimize side effects and maximize treatment efficacy.
Application
Deruxtecan is prescribed for patients diagnosed with certain types of advanced solid tumors who have not responded to standard therapies. It is typically used in combination with other medications to enhance treatment outcomes. The decision to prescribe Deruxtecan is based on the type of cancer, the patient's overall health condition, and the potential benefits versus risks. Healthcare professionals will conduct thorough assessments to determine eligibility for this treatment option.
Articles:
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Publication Date: June 5, 2022
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Maria Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil-Gil, Wei Li, Jean-Yves Pierga, Seock-Ah Im, Halle C.F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung-Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Pharm.D., Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck and David A. Cameron
https://doi.org/10.1056/NEJMoa2203690
- The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
Publication Date: 2019
Takashi Nakada , Kiyoshi Sugihara, Takahiro Jikoh, Yuki Abe, Toshinori Agatsuma
https://doi.org/10.1248/cpb.c18-00744
- Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Publication Date: May 04, 2021
Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Marwan Fakih, Elena Elez, Javier Rodriguez, Fortunato Ciardiello, Yoshito Komatsu, Taito Esaki, Ki Chung, Zev Wainberg, Andrea Sartore-Bianchi, Kapil Saxena, Eriko Yamamoto, Emarjola Bako, Yasuyuki Okuda, Javad Shahidi, Axel Grothey, Takayuki Yoshino